Email this article Cost-Effectiveness of Drug Eluting Stents Versus Bare Metal Stents in Coronary Heart
Abstract
Objective
The purpose of this study was to perform a systematic literature review to determine whether coronary disease endovascular
therapy with drug eluting stents (DES) compared with bare metal stents (BMS) is cost-effective.
Methods
A systematic review was performed in Pubmed/Medline, Embase, CDRS, NCBI, Hinari, CRD, DARE, NHSEED, HTA,
HSRPROJ, HSTAT electronic databases to identify full economic evaluation studies with health care perspective reporting
the relationship between cost/absolute risk reduction and cost/QALY, without date or language limitations.
Results
Sixteen studies were included (21807 participants). Paclitaxel or sirolimus DES compared with BMS were evaluated in five
studies (31.25%), 31.25% assessed only sirolimus eluting stents, 25% only paclitaxel eluting stents and 12.5% zotarolimus
eluting stents. Health care payment perspective was explicit in 93.75% of the studies. The distribution of patient characteristics was similar in all groups and balanced in observational studies. Six of the 16 studies concluded that DES were not cost-effective in their population, but that in subgroups at greater risk of restenosis or with multiple vessel disease the therapy was cost-effective.
Conclusions
The studies were consistent in the reduction of target vessel revascularization frequency with DES compared
to BMS without affecting mortality at 12 month follow-up. The intervention was cost-effective in studies at greater risk of restenosis or with multiple vessel disease.
References
Aponte J, Eslava-Schmalbach J, Díaz-Rojas J, Gaitán-Duarte H. Interpreting cost-effectiveness analysis studies in gynecology. Revista Colombiana de Obstetricia y Ginecología 2011;62(2):177-87.
Laxminarayan R, Chow J, Shahid-Salles S. La costo-efectividad de las intervenciones: repaso general de las ideas más importantes. In: Press OU, editor. Disease Control Priorities in Developing Countries. 2 ed2006. p. 40-105.
O´Brien B. Principles of Economic Evaluation for Health Care Programmes. J Rheumatol. 1995;22:1399-042.
Neyt M, Van Brabandt H, Devriese S, Mahieu J, De Ridder A, De Graeve D, et al. Drug Eluting Stents in Belgium: Health Technology Assessment Health Technology Assessment. 2007.
O'Neill W, Leon MB. Drug-Eluting Stents : Costs Versus Clinical Benefit. Circulation. 2003;107:3008-11.
Vlaar P, Bart JGLdS, Zijlstra F. DES or BMS in acute myocardial infarction? European Heart Journal. 2007;28:2693-4.
Lemos PA, Serruys P, Sousa E. Drug-Eluting Stents. Cost Versus Clinical Benefit Circulation. 2003;107:3003-7.
Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions The Cochrane Collaboration and John Wiley & Sons Ltd.; 2008.
Pfisterer ME. Commentary on drug-eluting stents: to use or not to use -that is the question! NICE guidelines for the use of drug-eluting stents: how do we establish worth? Heart. 2008;94:1648-50.
Sunil G, Eisenberg MJ. Drug-Eluting Stents More Dollars Than Sense? Journal of the American College of Cardiology: Cardiovascular Interventions. 2009;2(12):1188-9.
Robinson R. Economic Evaluation and Health Care. What does it mean? British Medical Journal. 1993;307:670-3.
Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275-83.
Cunningham S. Current Products and Practice. An Introduction to Economic Evaluation of Health Care. Current Products and Practice. 2001;28(3):246-50.
Hwang SE, Chen KG, Yin WH, Tsai WH, Yeh MY. Cost-effectiveness analyses of drug-eluting versus bare-metal stents. Journal of Internal Medicine of Taiwan. 2010;21(4):258-69.
Cohen DJ, Bakhai A, Shi CX, Githiora L, Lavelle T, Berezin RH, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses - Results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation. 2004;110(5):508-14.
Rinfret S, Cohen DJ, Tahami Monfared AA, LeLorier J, Mireault J, Schampaert E. Cost Effectiveness of the Sirolimus-Eluting Stent in High-Risk Patients in Canada: An Analysis from the C-SIRIUS Trial. American Journal of Cardiovascular Drugs. 2006;6(3):159-68.
Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, et al. Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization: Results From the TAXUS-IV Trial. Journal of the American College of Cardiology. 2006;48(2):253-61.
Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, et al. Long-Term Clinical and Economic Analysis of the Endeavor Zotarolimus-Eluting Stent Versus the Cypher Sirolimus-Eluting Stent 3-Year Results From the ENDEAVOR III Trial (Randomized Controlled Trial of the Medtronic Endeavor Drug ABT-578 Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). Jacc-Cardiovascular Interventions. 2009;2(12):1199-207.
Remak E, Manson S, Hutton J, Brasseur P, Olivier E, Gershlick A. Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data. Eurointervention. 2010;5:826-32.
Varani E, Gastaroba P, Di Tanna GL, Saia F, Balducelli M, Campo G, et al. Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation. Eurointervention. 2010;5:953-61.
Russell S, Antoñanzas F, Mainar V. Impacto económico del stent coronario Taxus: implicaciones para el sistema sanitario español Revista Española de Cardiología. 2006;59(9):889-96.
Ekman M, Sjogren I, James S. Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system Scandinavian Cardiovascular Journal. 2006;40:17-24.
Polanczyk CA, Wainstein MV, Ribeiro JP. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil. Arquivos Brasileiros De Cardiologia. 2007;88(4):464-74.
Ong ATL, Daemen J, van Hout BA, Lemos PA, Bosch JL, van Domburg RT, et al. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. European Heart Journal. 2006;27(24):2996-3003.
Brunner-La Rocca HP, Kaiser C, Pfisterer M, Investigators B. Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). European Heart Journal. 2007;28(6):719-25.
Goeree R, Bowen JM, Blackhouse G, Lazzam C, Cohen E, Chiu M, et al. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario. International Journal of Technology Assessment in Health Care. 2009;25(02):196-207.
Ferreira E, Vianna D, Pereira V, Vargues C, Ferreira A, de Lellis C, et al. Analysis of the Cost-effectiveness of Drug-Eluting and Bare-Metal Stents in Coronary Disease. Arq Bras Cardiol. 2010;94(3):286-92.
Neyt M, De Laet C, De Ridder A, Van Brabandt H. Cost Effectiveness of Drug-Eluting Stents In Belgian Practice. Pharmacoeconomics. 2009;27(4):313-27.
Sugimoto K, Kobayashi Y, Kuroda N, Komuro I. Cost Analysis of Sirolimus-Eluting Stents in the Japanese Health Insurance System. International Heart Journal. 2009;50(6):723-30.
Hung C-S, Cheng C-L, Chao C-L, Kao H-L, Chen M-F, Lin N-P. Cost-effectiveness of Drug-eluting Stents in Patients With Stable Coronary Artery Disease Journal of the Formosan Medical Association. 2011;110(2):109-14.
Full Text
Refbacks
- There are currently no refbacks.
The documents published in this journal are under the licencia Creative Commons Atribución-NoComercial-Compartir-Igual 2.5 Argentina.
Revista argentina de cardiología. ISSN en línea 1850-3748. Argentine journal of cardiology (English ed. Online ISSN 2314-2286) Sociedad Argentina de Cardiología. Azcuénaga 980 (C1115AAD),Ciudad Autónoma de Buenos Aires, República Argentina. Tel. (54 11) 4961-6027/8/9 Fax: 4961-6020 www.sac.org.ar revista@sac.org.ar